Bausch Health Companies Inc. (BHC)
Bausch Health Companies Inc., together with its associated entities, is engaged in the development, manufacturing, and commercialization of a diverse portfolio of pharmaceutical products, medical devices, and over-the-counter remedies. Its primary therapeutic focus areas include ophthalmology, digestive health, and dermatology. The enterprise conducts its operations through five principal divisions: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment is dedicated to vision care, encompassing surgical instruments, consumer eye health products, and ophthalmic pharmaceuticals. Salix specializes in delivering gastroenterology-specific products exclusively within the United States. The International Rx division markets Solta products, a range of branded and generic pharmaceuticals, OTC items, medical devices, and Bausch + Lomb offerings across diverse geographies including Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. Ortho Dermatologics focuses on dermatological products in the U.S., in addition to distributing Solta's medical aesthetic devices globally. Finally, the Diversified Products segment supplies pharmaceutical solutions for neurology and other therapeutic categories, as well as generic medications and dental products, all within the U.S. The company was formerly known as Valeant Pharmaceuticals International, Inc., officially changing its name to Bausch Health Companies Inc. in July 2018. Its corporate headquarters are located in Laval, Canada.
Sector: Pharmaceutical Preparations
Industry: Drug Manufacturers - Specialty & Generic
Bausch Health Companies Inc.
Recent SEC filings with analysis
- 10-QBausch Health delivered a strong Q3 2026: revenues rose to $2,941M from $2,681M a year ago, with diluted EPS of $1.15 versus $0.48, and Salix segment profit up…
- 8-KBausch Health delivered a strong Q3 2026, with consolidated revenue of $2.94 billion (up 10% reported, 8% organic) and adjusted EPS of $1.77 versus $1.16 a…